寻找一种有效、安全且通用的抗HIV疫苗：仅在一种短肽中找到答案。
Searching for an effective, safe and universal anti-HIV vaccine: Finding the answer in just one short peptide.
作者信息
Lucchese Guglielmo, Stufano Angela, Kanduc Darja
机构信息
Department of Biochemistry and Molecular Biology; University of Bari; Bari, Italy.
出版信息
Self Nonself. 2011 Jan;2(1):49-54. doi: 10.4161/self.2.1.14762. Epub 2011 Jan 1.
Abstract
We explore the pentapeptide overlapping between human immunodeficiency virus (HIV) proteins and the human proteome. Our intent was to define viral peptides to be used in vaccines effective against different HIV strains, vaccines that are able to overcome the difficulties posed by the tendency of HIV to mutate, and that are also exempt from harmful collateral cross-reactions, as well as being repeatedly administrable to the global population. Analysis of HIV-1 envelope glycoprotein 160 (Env gp160) sequences revealed a set of 15 pentapeptides highly conserved among a number of retroviral sequences, and absent in the human proteome, thus representing unique molecular retroviral signatures. Use of these short viral peptide modules may represent the first concrete step toward the goal of a universal, safe and effective anti-HIV vaccine.
摘要
我们探索了人类免疫缺陷病毒（HIV）蛋白与人类蛋白质组之间重叠的五肽。我们的目的是确定可用于有效对抗不同HIV毒株的疫苗的病毒肽，这些疫苗能够克服HIV突变倾向带来的困难，并且也不会产生有害的附带交叉反应，同时还能对全球人群反复给药。对HIV-1包膜糖蛋白160（Env gp160）序列的分析揭示了一组15个五肽，它们在许多逆转录病毒序列中高度保守，而在人类蛋白质组中不存在，因此代表了独特的分子逆转录病毒特征。使用这些短的病毒肽模块可能是朝着通用、安全和有效的抗HIV疫苗目标迈出的第一步。
相似文献
1
Searching for an effective, safe and universal anti-HIV vaccine: Finding the answer in just one short peptide.寻找一种有效、安全且通用的抗HIV疫苗：仅在一种短肽中找到答案。
Self Nonself. 2011 Jan;2(1):49-54. doi: 10.4161/self.2.1.14762. Epub 2011 Jan 1.
2
Applying the Concept of Peptide Uniqueness to Anti-Polio Vaccination.将肽独特性概念应用于抗脊髓灰质炎疫苗接种
J Immunol Res. 2015;2015:541282. doi: 10.1155/2015/541282. Epub 2015 Oct 19.
3
Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge.人类免疫缺陷病毒 C.1086 包膜 gp140 蛋白增强剂在 DNA/改良安卡拉牛痘病毒疫苗接种后未能增强针对 V1V2 抗体的异源反应和对 C 型猴免疫缺陷病毒攻击的保护。
J Virol. 2019 Sep 30;93(20). doi: 10.1128/JVI.00934-19. Print 2019 Oct 15.
4
Vaccinia and other viruses with available vaccines show marked homology with the HIV-1 envelope glycoprotein: the prospect of using existing vaccines to stem the AIDS pandemic.天花和其他有可用疫苗的病毒与 HIV-1 包膜糖蛋白具有显著的同源性：利用现有疫苗遏制艾滋病大流行的前景。
Immunopharmacol Immunotoxicol. 2012 Apr;34(2):222-31. doi: 10.3109/08923973.2011.596542. Epub 2011 Aug 19.
5
Analysis of the human env-specific cytotoxic T-lymphocyte (CTL) response in natural human immunodeficiency virus type 1 infection: low prevalence of broadly cross-reactive env-specific CTL.对自然感染人类免疫缺陷病毒1型的人群中env特异性细胞毒性T淋巴细胞（CTL）反应的分析：广泛交叉反应性env特异性CTL的低流行率
J Virol. 1996 Dec;70(12):8468-76. doi: 10.1128/JVI.70.12.8468-8476.1996.
6
Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection.早期HIV-1 B亚型感染中跨亚型包膜糖蛋白160特异性CD8 +细胞毒性T淋巴细胞反应
AIDS Res Hum Retroviruses. 1998 Jul 20;14(11):925-37. doi: 10.1089/aid.1998.14.925.
7
Peptides for Anti-Ebolavirus Vaccines.用于抗埃博拉病毒疫苗的肽
Curr Drug Discov Technol. 2016;13(4):225-231. doi: 10.2174/1570163813666160902131603.
8
Rhesus macaques vaccinated with consensus envelopes elicit partially protective immune responses against SHIV SF162p4 challenge.恒河猴接种共识包膜后，可引发针对 SHIV SF162p4 挑战的部分保护性免疫反应。
Virol J. 2013 Apr 2;10:102. doi: 10.1186/1743-422X-10-102.
9
Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization.1型人类免疫缺陷病毒A至G序列亚型功能性包膜基因的分子克隆与分析。世界卫生组织和美国国立过敏与传染病研究所艾滋病毒分离与鉴定网络。
J Virol. 1996 Mar;70(3):1651-67. doi: 10.1128/JVI.70.3.1651-1667.1996.
10
Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C.一种表达HIV-1包膜1086 C亚型的重组、具有复制能力的腺病毒4型载体疫苗的临床前开发。
PLoS One. 2013 Dec 3;8(12):e82380. doi: 10.1371/journal.pone.0082380. eCollection 2013.
引用本文的文献
1
Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy.SARS-CoV-2 的分子变体：抗原特性和当前疫苗效力。
Med Microbiol Immunol. 2022 Jun;211(2-3):79-103. doi: 10.1007/s00430-022-00729-6. Epub 2022 Mar 2.
2
An Epitope Platform for Safe and Effective HTLV-1-Immunization: Potential Applications for mRNA and Peptide-Based Vaccines.用于安全有效 HTLV-1 免疫的表位平台：mRNA 和肽基疫苗的潜在应用。
Viruses. 2021 Jul 27;13(8):1461. doi: 10.3390/v13081461.
3
Synthetic immunotherapy induces HIV virus specific Th1 cytotoxic response and death of an HIV-1 infected human cell line through classic complement activation.合成免疫疗法通过经典补体激活诱导 HIV 病毒特异性 Th1 细胞毒性反应，并导致 HIV-1 感染的人细胞系死亡。
Virol J. 2013 Apr 4;10:107. doi: 10.1186/1743-422X-10-107.
4
Peptide sharing between influenza A H1N1 hemagglutinin and human axon guidance proteins.甲型H1N1流感病毒血凝素与人轴突导向蛋白之间的肽段共享
Schizophr Bull. 2014 Mar;40(2):362-75. doi: 10.1093/schbul/sbs197. Epub 2013 Jan 31.
5
Selfness-nonselfness in designing an anti-B19 erythrovirus vaccine.抗B19微小病毒疫苗设计中的自身与非自身问题
Self Nonself. 2011 Apr;2(2):114-119. doi: 10.4161/self.2.2.16190. Epub 2011 Apr 1.
6
HCV: Written in our DNA.丙型肝炎病毒：写在我们的基因里。
Self Nonself. 2011 Apr;2(2):108-113. doi: 10.4161/self.2.2.15795. Epub 2011 Apr 1.
本文引用的文献
1
Charting the peptide crossreactome between HIV-1 and the human proteome.绘制HIV-1与人类蛋白质组之间的肽交叉反应组图谱。
Front Biosci (Elite Ed). 2011 Jun 1;3(4):1385-400. doi: 10.2741/e341.
2
Clustering of rare peptide segments in the HCV immunome.丙型肝炎病毒免疫组中稀有肽段的聚类
Self Nonself. 2010 Apr;1(2):154-162. doi: 10.4161/self.1.2.11391. Epub 2010 Feb 3.
3
The self/nonself issue: A confrontation between proteomes.自我/非自我问题：蛋白质组之间的对抗。
Self Nonself. 2010 Jul;1(3):255-258. doi: 10.4161/self.1.3.11897. Epub 2010 Jan 29.
4
Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine.STEP 和 Phambili 试验结果概述：两项 IIb 期概念验证试验，研究了 MRK 腺病毒 5 型 gag/pol/nef 亚型 B HIV 疫苗的疗效。
Curr Opin HIV AIDS. 2010 Sep;5(5):357-61. doi: 10.1097/COH.0b013e32833d2d2b.
5
Human immunodeficiency virus-1 vaccine design: where do we go now?人类免疫缺陷病毒-1 疫苗设计：我们现在该往何处去？
Immunol Cell Biol. 2011 Mar;89(3):367-74. doi: 10.1038/icb.2010.118. Epub 2010 Oct 19.
6
Proposing low-similarity peptide vaccines against Mycobacterium tuberculosis.提出针对结核分枝杆菌的低相似性肽疫苗。
J Biomed Biotechnol. 2010;2010:832341. doi: 10.1155/2010/832341. Epub 2010 Jun 3.
7
4E10-resistant HIV-1 isolated from four subjects with rare membrane-proximal external region polymorphisms.从四位具有罕见膜近端外区多态性的个体中分离出的 4E10 耐药 HIV-1。
PLoS One. 2010 Mar 23;5(3):e9786. doi: 10.1371/journal.pone.0009786.
8
Is an HIV vaccine possible?艾滋病疫苗是否可行？
Braz J Infect Dis. 2009 Aug;13(4):304-10. doi: 10.1590/s1413-86702009000400013.
9
Protein information content resides in rare peptide segments.蛋白质信息含量存在于罕见的肽段中。
Peptides. 2010 May;31(5):983-8. doi: 10.1016/j.peptides.2010.02.003. Epub 2010 Feb 11.
10
ON THE SEROLOGICAL SPECIFICITY OF PEPTIDES. III.肽的血清学特异性研究. III.
J Exp Med. 1939 Apr 30;69(5):705-19. doi: 10.1084/jem.69.5.705.
Zotero 插件